315 related articles for article (PubMed ID: 32647940)
1. Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.
Du ZL; Wang Y; Wang DY; Zhang L; Bian ZM; Deng Y; Xu CS; Lin DC; Xie L; Jia Y; Gao JD; Zhang BL
Breast Cancer Res Treat; 2020 Sep; 183(2):429-438. PubMed ID: 32647940
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer.
Zhai Z; Zheng Y; Yao J; Liu Y; Ruan J; Deng Y; Zhou L; Zhao P; Yang S; Hu J; We B; Wu Y; Zhang D; Kang H; Dai Z
JAMA Netw Open; 2020 Nov; 3(11):e2021881. PubMed ID: 33211105
[TBL] [Abstract][Full Text] [Related]
3. Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer.
Carbajal-Ochoa W; Bravo-Solarte DC; Bernal AM; Anampa JD
Breast Cancer Res Treat; 2024 Jan; 203(2):257-269. PubMed ID: 37833449
[TBL] [Abstract][Full Text] [Related]
4. The different outcomes between breast-conserving surgery and mastectomy in triple-negative breast cancer: a population-based study from the SEER 18 database.
Chen QX; Wang XX; Lin PY; Zhang J; Li JJ; Song CG; Shao ZM
Oncotarget; 2017 Jan; 8(3):4773-4780. PubMed ID: 27999201
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer.
Yao Y; Chu Y; Xu B; Hu Q; Song Q
Cancer Med; 2019 Feb; 8(2):554-563. PubMed ID: 30632300
[TBL] [Abstract][Full Text] [Related]
6. Are we overtreating stage I triple-negative breast cancer in Ontario? A population-based retrospective epidemiological analysis using the ICES database.
Shum K; Hussein A; Hamm C
Med Oncol; 2022 Sep; 39(12):228. PubMed ID: 36175693
[TBL] [Abstract][Full Text] [Related]
7. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
Bouchalova K; Svoboda M; Kharaishvili G; Vrbkova J; Bouchal J; Trojanec R; Koudelakova V; Radova L; Cwiertka K; Hajduch M; Kolar Z
Tumour Biol; 2015 Jun; 36(6):4243-52. PubMed ID: 25616695
[TBL] [Abstract][Full Text] [Related]
8. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
[TBL] [Abstract][Full Text] [Related]
9. Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.
Wu W; Wu M; Peng G; Shi D; Zhang J
Cancer Med; 2019 Dec; 8(18):7523-7531. PubMed ID: 31642210
[TBL] [Abstract][Full Text] [Related]
10. The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy.
Fu WF; Chen QX; Wang XX; Zhang J; Song CG
Front Oncol; 2020; 10():1753. PubMed ID: 33102205
[No Abstract] [Full Text] [Related]
11. Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database.
Chen HL; Zhou MQ; Tian W; Meng KX; He HF
PLoS One; 2016; 11(10):e0165409. PubMed ID: 27798652
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy in small node-negative triple-negative breast cancer.
Steenbruggen TG; van Werkhoven E; van Ramshorst MS; Dezentjé VO; Kok M; Linn SC; Siesling S; Sonke GS
Eur J Cancer; 2020 Aug; 135():66-74. PubMed ID: 32554215
[TBL] [Abstract][Full Text] [Related]
13. T1-2N0M0 Triple-Negative Breast Cancer Treated With Breast-Conserving Therapy Has Better Survival Compared to Mastectomy: A SEER Population-Based Retrospective Analysis.
Li H; Chen Y; Wang X; Tang L; Guan X
Clin Breast Cancer; 2019 Dec; 19(6):e669-e682. PubMed ID: 31375327
[TBL] [Abstract][Full Text] [Related]
14. Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy?
Guo L; Xie G; Wang R; Yang L; Sun L; Xu M; Yang W; Chung MC
BMC Cancer; 2021 Jun; 21(1):717. PubMed ID: 34147061
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Use and Impact of Chemotherapy in Lymph Node-Negative, T1a Triple-Negative Breast Cancer.
Bravo-Solarte DC; Zhang F; Anampa JD
Clin Breast Cancer; 2023 Oct; 23(7):763-773.e6. PubMed ID: 37648557
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.
Gu Y; Wu G; Zou X; Huang P; Yi L
Med Sci Monit; 2020 Feb; 26():e920432. PubMed ID: 32043484
[TBL] [Abstract][Full Text] [Related]
17. Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis.
Crozier JA; Pezzi TA; Hodge C; Janeva S; Lesnikoski BA; Samiian L; Devereaux A; Hammond W; Audisio RA; Pezzi CM
Lancet Oncol; 2020 Dec; 21(12):1611-1619. PubMed ID: 33271091
[TBL] [Abstract][Full Text] [Related]
18. Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study.
Roy S; Lakritz S; Schreiber AR; Kuna EM; Bradley CJ; Kondapalli L; Diamond JR
Eur J Cancer; 2024 Jan; 196():113426. PubMed ID: 38000217
[TBL] [Abstract][Full Text] [Related]
19. The impact of chemotherapy and survival prediction by machine learning in early Elderly Triple Negative Breast Cancer (eTNBC): a population based study from the SEER database.
Huang K; Zhang J; Yu Y; Lin Y; Song C
BMC Geriatr; 2022 Apr; 22(1):268. PubMed ID: 35361134
[TBL] [Abstract][Full Text] [Related]
20. Survival benefit of adjuvant chemotherapy in elderly patients with stage I triple-negative breast cancer: a cohort study based on the SEER database.
Zhang Y; Liu X; Ma M; Chen C; Wang X
Transl Cancer Res; 2023 Jul; 12(7):1741-1752. PubMed ID: 37588733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]